Fibromyalgia

EULAR/PReS Standards for Transitional Care of Juvenile-Onset Rheumatic Diseases

Panel advises that up to 50% of young patients with juvenile-onset rheumatic diseases fail to successfully transition to adult rheumatology services.

Clinician Roundtable: Effective Management of Noninfectious Uveitis

Autoimmune uveitis is usually a diagnosis of exclusion. Part of the challenge of effective management of noninfectious uveitis is that it is not really a ...

Video Review: Differentiating Septic and Reactive Arthritis

Seronegative spondyloarthropathies associated with human leukocyte antigen (HLA) B27 antigens can manifest as an acute inflamed joint and must be differentiated from septic arthritis.

Lead Investigator Discusses Phase 3 Trial of IL-17A Inhibitor in PsA

Philip Mease, MD, clinical professor, University of Washington School of Medicine, Seattle, discusses the treatment of psoriatic arthritis (PsA) by inhibiting interleukin (IL)-17A with the ...

When Should Rheumatologists Refer Patients for Evaluation by an Orthopedic Surgeon?

Michael M. Alexiades, MD, met with Rheumatology Advisor to discuss the timely referral of patients with inflammatory arthritides who may be candidates for operative intervention.

Evaluation of the Pediatric Patient With Joint Pain and Swelling

Watch a video providing a comprehensive review of the distinguishing factors between the presentation of septic arthritis and Lyme arthritis.

VIDEO: Discussing the Use of Biosimilars for Rheumatic Disease

Discussion of the recent introduction of biosimilar agents into the treatment armamentarium for rheumatic disease.

Delayed Recognition of Spondyloarthritis: Diagnostic Challenges & Opportunities

Delayed diagnosis is associated with worse outcomes and poor treatment responses in patients with spondyloarthritis. Andrew Vreede, MD, University of Wisconsin School of Medicine and ...

Looking Beyond Corticosteroids to Treat Noninfectious Uveitis

The recent US Food and Drug Administration (FDA) approval of adalimumab (Humira®, AbbVie) for the treatment of noninfectious intermediate, posterior, and pan-uveitis is the first ...

Looking Beyond Traditional CV Risk Factors to Predict CV Events in PsA

In addition to traditional cardiovascular risk factors, increased PsA disease activity also appears to increase cardiovascular risk.

Latest News

Spondyloarthritis High Coronary Plaque Burden Is Independent of Metabolic Syndrome in Psoriatic Arthritis

High Coronary Plaque Burden Is Independent of Metabolic Syndrome in Psoriatic Arthritis

Psoriatic arthritis is associated with accelerated coronary plaque formation, particularly mixed plaques, independent of metabolic disease.

Spondyloarthritis Increased HLA-B27 Associated With More Severe Sonographic Enthesitis in PsA

Increased HLA-B27 Associated With More Severe Sonographic Enthesitis in PsA

In patients with psoriatic arthritis, increasing levels of HLA-B27 are associated with more severe sonographic enthesitis.

Spondyloarthritis Functional Status in Early Axial Spondyloarthritis: The Role of Spinal Structural Damage

Functional Status in Early Axial Spondyloarthritis: The Role of Spinal Structural Damage

Results of the GESPIC study found that structural damage in the spine and disease activity were both determinants of functional status and spine mobility in patients with early axial spondyloarthritis.

Spondyloarthritis Sustained Reduction in axSpA Joint Inflammation With Certolizumab Pegol

Sustained Reduction in axSpA Joint Inflammation With Certolizumab Pegol

Decreases in spinal and sacroiliac joint inflammation on MRI were maintained through 204 weeks with certolizumab pegol treatment.

Spondyloarthritis Spondyloarthritis Increases Risk for Dysrhythmias and Aortic Regurgitation

Spondyloarthritis Increases Risk for Dysrhythmias and Aortic Regurgitation

The risk for aortic regurgitation and cardiac rhythm abnormalities was evaluated in a nationwide cohort of patients with spondyloarthritis.

Psoriatic Arthritis Efficacy and Safety of Ixekizumab Evaluated in Active Psoriatic Arthritis

Efficacy and Safety of Ixekizumab Evaluated in Active Psoriatic Arthritis

Results from the phase 3 SPIRIT-P1 study show that treatment with ixekizumab every 2 or 4 weeks in patients with active psoriatic arthritis demonstrated sustained efficacy and a favorable safety profile.

Spondyloarthritis Efficacy of Apremilast Monotherapy Assessed in Biologic-Naive Psoriatic Arthritis

Efficacy of Apremilast Monotherapy Assessed in Biologic-Naive Psoriatic Arthritis

Patients with psoriatic arthritis who are taking apremilast experienced early symptom relief and sustained clinical improvement through 1 year of treatment.

Ankylosing Spondylitis Biologic DMARDs Do Not Reduce Spinal Fracture Risk in Ankylosing Spondylitis

Biologic DMARDs Do Not Reduce Spinal Fracture Risk in Ankylosing Spondylitis

Spinal fracture-free survival among patients with AS was not significantly affected by the use of bDMARD therapy.

Spondyloarthritis Use of Secukinumab in Ankylosing Spondylitis: Efficacy and Safety

Use of Secukinumab in Ankylosing Spondylitis: Efficacy and Safety

Investigators examined the long-term safety and efficacy of a subcutaneous maintenance dose of secukinumab 150 and 300 mg.

Spondyloarthritis Do Biologic DMARDs Affect Spinal Fracture Risk in Ankylosing Spondylitis?

Do Biologic DMARDs Affect Spinal Fracture Risk in Ankylosing Spondylitis?

Male gender and the Charlson Comorbidity Index score contributed significantly to fracture risk in this population.

Sign Up for Free e-newsletters